Volume | 4,745 |
|
|||||
News | - | ||||||
Day High | 5.92 | Low High |
|||||
Day Low | 5.61 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Precipio Inc | PRPO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
5.65 | 5.61 | 5.92 | 5.84 | 5.7902 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
59 | 4,745 | US$ 5.80 | US$ 27,528 | - | 4.7515 - 9.968 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:10:35 | 30 | US$ 5.70 | USD |
Precipio Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
8.29M | 1.42M | - | 15.2M | -5.85M | -4.12 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Precipio News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PRPO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.7694 | 5.92 | 5.50 | 5.78 | 1,622 | 0.0706 | 1.22% |
1 Month | 6.50 | 6.50 | 5.50 | 5.90 | 3,268 | -0.66 | -10.15% |
3 Months | 6.26 | 7.00 | 5.50 | 6.15 | 4,053 | -0.42 | -6.71% |
6 Months | 6.42 | 7.30 | 5.0039 | 6.32 | 5,187 | -0.58 | -9.03% |
1 Year | 9.60 | 9.968 | 4.7515 | 6.86 | 53,761 | -3.76 | -39.17% |
3 Years | 75.80 | 93.00 | 4.7515 | 43.21 | 204,400 | -69.96 | -92.30% |
5 Years | 84.00 | 183.60 | 4.7515 | 81.36 | 1,210,106 | -78.16 | -93.05% |
Precipio Description
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provide new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. |